CFTR modulators are especially crucial in the pediatric population because early intervention can significantly improve clinical outcomes. By addressing the root cause of CF from a young age, these medications can potentially reduce disease progression and improve quality of life. Early use may also help in maintaining better lung function and reducing the frequency of lung infections.
